Medicinal Organic Cannabis (MOCA) is excited to introduce our fully organic crop of Cannabigerol (CBG) to the Australian market. CBG is one of over 120 types of cannabinoids found in the cannabis plant, and is known as the “mother of all cannabinoids”. Our CBG is grown using sustainable and organic practices and is now available for purchase by compounding pharmacies in Australia.

CBG is processed by the body’s endocannabinoid system, which is responsible for keeping our bodies in an optimal state. Research has shown that CBG may have a host of promising potential benefits. These include, but are not limited to:

1. Anti-inflammatory properties - CBG has been found to have powerful anti-inflammatory properties, which can help reduce pain and inflammation.

2. Neuroprotective effects - Studies have shown that CBG may help protect brain cells from damage, making it a promising treatment for neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

3. Antidepressant properties - CBG has been found to have antidepressant properties, which may make it a useful treatment for depression and anxiety.

4. Antimicrobial effects - CBG has been found to have potent antimicrobial effects, making it a promising treatment for bacterial infections such as MRSA.

5. Pain relief - CBG has been found to have analgesic properties, making it a useful treatment for pain relief.

In the past, CBG was mainly known as a “minor cannabinoid”. However, recent research has shown that it is present in high percentages in the cannabis plant at the beginning of the flowering phase. It is also the first substance to develop in the plant, in the acid form CBGA. It is from CBGA that other cannabinoids such as THC and CBD are derived.

The production difficulties of CBG make it very scarce. It is much harder to produce than other cannabinoids like THC and CBD. Since CBG shares many similarities with CBD, manufacturers would rather produce CBD. However, MOCA is committed to producing CBG using sustainable and organic practices, and we believe that it has the potential to be an important cannabinoid in the medical cannabis industry.

Our CBG is grown using the “seed to sale” approach, which means that we are involved in all aspects of the supply chain. This allows us to ensure that our manufacturing meets our standards and vision. Our commitment to sustainability is also reflected in our business model, which is based on the three P’s - People, Planet, and Profit. We consider this the ethical measure of businesses, and our investment principles take into account the impact on the environment, the social perspective, and our corporate governance.

At MOCA, we believe that sustainability is the future, and with our unique mix of experience and skills, our sustainable management team of professionals can build some of the most prosperous triple bottom line companies in the world. Our triple bottom line accounting expands the traditional reporting framework to take into account social and environmental performance in addition to financial performance.

In conclusion, MOCA’s fully organic crop of Cannabigerol (CBG) is a promising addition to the medical cannabis industry. As research into the potential benefits of CBG continues, we believe that it has the potential to be an important cannabinoid in the treatment of a range of medical conditions. Our commitment to sustainability and organic practices ensures that our CBG is of the highest quality, and we are excited to offer it to compounding pharmacies in Australia.

References 

1. Pagano E, Montanaro V, Di Girolamo A, Pistone A, Altieri V, Zjawiony JK, Izzo AA, Capasso R. Effect of non-psychotropic plant-derived cannabinoids on bladder contractility: focus on cannabigerol. Nat Prod Commun. 2015 May;10(5):1009-12. PMID: 26197538.

2. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology (Berl). 2016 Apr;233(19-20):3603-13. doi: 10.1007/s00213-016-4371-0. Epub 2016 Aug 3. PMID: 27493229; PMCID: PMC5021743.

3. Romano B, Pagano E, Orlando P, Capasso R, Cascio MG, Pertwee RG, Marzo VD, Izzo AA, Borrelli F. Pure Δ(9)-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ(9)-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol Res. 2016 Sep;111:405-10. doi: 10.1016/j.phrs.2016.06.005. Epub 2016 Jun 13. PMID: 27302842.

4. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013 May 1;85(9):1306-16. doi: 10.1016/j.bcp.2013.01.017. Epub 2013 Feb 4. PMID: 23392469.

5. Oláh A, Markovics A, Szabó-Papp J, Szabó PT, Stott C, Zouboulis CC, Bíró T. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp Dermatol. 2016 Sep;25(9):701-7. doi: 10.1111/exd.13042. Epub 2016 Jun 20. PMID: 27229521.

6. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol. 2011 Mar;162(3):584-96. doi: 10.1111/j.1476-5381.2010.01063.x. PMID: 21091673; PMCID: PMC3041249.

Please note that while these references support the health properties of CBG, it is important to consult with a healthcare professional for personalized advice and guidance regarding the use of CBG or any other cannabinoid for specific health conditions.